UAE: Professor makes breakthrough in targeted drug delivery for cancer therapy – News

An AUS team has even applied for a patent on using antibodies on the surface of nanocarriers to treat breast cancer

Dr Ghaleb Husseini, Distinguished Professor at the American University of Sharjah (AUS), recently delivered an insightful lecture on Targeted Drug Delivery in Cancer Therapy as part of a Faculty of Engineering (CEN) Lecture Series, highlighting his work in ultrasound medicine New job delivery.

Professor Husseini is a faculty member in the AUS Department of Chemical and Biological Engineering and a leading researcher in the field of ultrasonic drug delivery. His work involves developing new drug delivery systems to minimize the side effects of chemotherapy. By encapsulating chemotherapy drugs in nanoscale carriers until they reach the tumor site, the body’s healthy cells can avoid interacting with anticancer drugs.

Ongoing research work at AUS involves the Drug Delivery Research Group, whose members are investigating new ways to enhance drug delivery to cancer cells. In addition to using ultrasound as a trigger mechanism, the team employed a biological lock and key (receptor binding) mechanism to improve drug accumulation and targeting at the tumor site.

By adding a key to the surface of nanocarriers that fit into cancer cell surface locks (receptors), the researchers hope to improve the efficacy of treatments while minimizing side effects.

The Drug Delivery Research Group was formed in 2012 and consists of AUS faculty, postgraduate and undergraduate students, and postdoctoral fellows. The group is currently conducting experiments to find the most effective ultrasound parameters (frequency, ultrasound intensity, and pulse duration) and has applied for a patent for the use of antibodies (i.e., the key is the antibody) on nanocarriers and ultrasound surfaces. Treat breast cancer.

“Targeted drug delivery using ultrasound is a promising approach to reduce the side effects of chemotherapy and improve the efficacy of cancer treatment. Our research aims to develop safe and effective nanocarriers that can selectively deliver chemotherapy drugs to tumor sites while protecting healthy tissue.

I am excited to share our findings and discuss the potential impact of this technology on the lives of cancer patients,” said Professor Husseini.

In the lecture, Prof. Husseini introduced his latest findings, showing that targeted drug delivery and ultrasound drug delivery can improve in vitro delivery by 200% compared with current clinically used technologies, and shared his insights into targeted drug delivery in cancer therapy. Insights for drug delivery.

In addition to discussing the benefits of targeted drug delivery, Professor Husseini provided valuable information on the process of obtaining a US patent in this area of ​​research.